Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cash Casey

Clinical Cardiac Electrophysiology Elmhurst, IL Medical Doctor

NPI 1518910306 CMS profile 250694

133 E Brush Hill Rd Ste 202, Elmhurst, IL 60126

Open in the dashboard

General payments

$287,219

1,136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cash Casey of Elmhurst, IL is reported in the CMS Open Payments database as having received $287,219 across 1,136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,568 100
2024 General $14,915 169
2023 General $24,863 132
2022 General $75,435 256
2021 General $37,645 113
2020 General $20,539 83
2019 General $108,254 283

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cash Casey
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Cash Casey were reported at $5,568. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Cash Casey Clinical Cardiac Electrophysiology median Middle half National median
2019 $108,254 $2,361 $585–$8,260 $163
2020 $20,539 $993 $247–$4,351 $114
2021 $37,645 $1,185 $326–$4,739 $132
2022 $75,435 $2,073 $554–$6,789 $149
2023 $24,863 $2,568 $759–$8,159 $160
2024 $14,915 $2,557 $703–$7,403 $164
2025 $5,568 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $207,320 469 payments
  2. Abbott Laboratories $52,056 136 payments
  3. Medtronic, Inc. $9,390 50 payments
  4. Boston Scientific Corporation $6,376 130 payments
  5. Biotronik Inc. $5,551 44 payments
  6. Pfizer Inc. $997 45 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $930 29 payments
  8. Novartis Pharmaceuticals Corporation $855 45 payments
  9. Amgen Inc. $770 38 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $408 26 payments
  11. Other $2,566 124 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $187,160 75 payments
  2. Consulting Fee $48,280 61 payments
  3. Travel and Lodging $27,411 98 payments
  4. Food and Beverage $24,368 902 payments
Products named General payments · program years 2019–2025
  1. XARELTO $207,237 469 payments
  2. ACCENT $11,695 18 payments
  3. Accent Pacemaker $11,105 9 payments
  4. ALLURE $5,530 11 payments
  5. Confirm Rx $5,067 10 payments
  6. Assurity Pacemaker $4,980 11 payments
  7. Ensite Cardiac Mapping System $3,195 4 payments
  8. Allure CRT Pacemaker $2,566 7 payments
  9. AVEIR $2,486 11 payments
  10. FARAPULSE $2,146 6 payments
  11. Other $23,144 638 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

6,811

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$2,053,403

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

34.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 1,032 $1,235,911
Eliquis Apixaban Brand 414 $454,714
Entresto Sacubitril/Valsartan Brand 108 $158,368
Multaq Dronedarone Hcl Brand 36 $66,720
Flecainide Acetate Generic 528 $26,942
Repatha Sureclick Evolocumab Brand 24 $23,835
Metoprolol Succinate Generic 902 $12,764
Brilinta Ticagrelor Brand 13 $12,628
Propafenone Hcl Er Propafenone Hcl Brand 45 $8,858
Amiodarone Hcl Generic 393 $8,521

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$698,126

Of which drugs: $1,631

Medicare patients

1,965

Average age 77

Services billed

11,189

1,021 women, 944 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Atrial fibrillation 52%
Ischemic heart disease 47%
Heart failure 40%
Diabetes 36%
Chronic kidney disease 36%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 25 100 $576

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
$8,352 1,032 —
JARDIANCE
$131 — —
Repatha
$125 24 —
ELIQUIS
$124 414 —
LEQVIO
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

1,136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record